Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jan 3;9(1):pkaf005.
doi: 10.1093/jncics/pkaf005.

Sex differences in melanoma survival-a GEM study

Tharani Murali  1 , Matthew Schwartz  2 , Adam Z Reynolds  3 , Li Luo  3 , Grace Ridgeway  1 , Klaus J Busam  4 , Anne E Cust  5 , Hoda Anton-Culver  6 , Richard P Gallagher  7 , Roberto Zanetti  8 , Stefano Rosso  8 , Lidia Sacchetto  9 , Colin B Begg  10 , Irene Orlow  10 , Nancy E Thomas  11 , Marianne Berwick  3 ; GEM Study Team
Collaborators, Affiliations

Sex differences in melanoma survival-a GEM study

Tharani Murali et al. JNCI Cancer Spectr. .

Abstract

Sex differences in melanoma are prominent, with female having a significant survival advantage. However, it is unclear why we see this survival advantage. Here, we investigate the relationship between sex, clinicopathologic variables, and melanoma specific survival in 1753 single primary melanomas from patients in the GEM (Genes, Environment, and Melanoma) study. Using Cox proportional hazard models and formal mediation analysis, the effect of sex on survival is explained largely by differences in the clinicopathologic features of tumors at diagnosis. Specifically, we find evidence that 86.5% of the effect of sex on melanoma survival is mediated by differences in age at diagnosis, Breslow thickness, ulceration, mitoses, and site (hazard ratio [HR] = 1.85, P < .001). This analysis indicates that the female survival advantage in melanoma is not primarily due to a direct effect of sex (HR = 1.19, P = .42) but is largely a result of an indirect effect of sex mediated by clinicopathologic features.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest to disclose.

References

    1. Arnold M, Singh D, Laversanne M, et al. Global burden of cutaneous melanoma in 2020 and projections to 2040. JAMA Dermatol. 2022;158:495-503. - PMC - PubMed
    1. Olsen CM, Thompson JF, Pandeya N, Whiteman DC. Evaluation of sex-specific incidence of melanoma. JAMA Dermatol. 2020;156:553-560. - PMC - PubMed
    1. Stidham KR, Johnson JL, Seigler HF. Survival superiority of females with melanoma: a multivariate analysis of 6383 patients exploring the significance of gender in prognostic outcome. Arch Surg. 1994;129:316-324. - PubMed
    1. de Vries E, Nijsten TEC, Visser O, et al. Superior survival of females among 1538 Dutch melanoma patients is independent of Breslow thickness, histologic type and tumor site. Ann Oncol. 2008;19:583-589. - PubMed
    1. Morgese F, Berardi R, Sampaolesi C, et al. Gender differences and outcome of melanoma patients. J Transl Med. 2015;13:P13.